{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:43:49Z","timestamp":1792550629859,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40265-024-02009-4","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:02:42Z","timestamp":1711105362000},"page":"599-606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Iptacopan: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"issue":"16","key":"2009_CR1","doi-asserted-by":"publisher","first-page":"7926","DOI":"10.1073\/pnas.1820892116","volume":"116","author":"A Schubart","year":"2019","unstructured":"Schubart A, Anderson K, Mainolfi N, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019;116(16):7926\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2009_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.htct.2020.06.006","volume":"43","author":"RD Cancado","year":"2021","unstructured":"Cancado RD, Araujo ADS, Sandes AF, et al. Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematol Transfus Cell Ther. 2021;43(3):341\u20138.","journal-title":"Hematol Transfus Cell Ther."},{"issue":"2","key":"2009_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00277-021-04715-5","volume":"101","author":"D Dingli","year":"2022","unstructured":"Dingli D, Matos JE, Lehrhaupt K, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022;101(2):251\u201363.","journal-title":"Ann Hematol"},{"issue":"1","key":"2009_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","volume":"105","author":"H Zhang","year":"2023","unstructured":"Zhang H, Rizk DV, Perkovic V, et al. Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 2023;105(1):189\u201399.","journal-title":"Kidney Int"},{"key":"2009_CR5","unstructured":"Novartis Pharmaceuicals. FABHALTA\u00ae (iptacopan) capsules, for oral use: US prescribing information. 2023. https:\/\/www.fda.gov. Accessed 18 Jan 2024."},{"key":"2009_CR6","unstructured":"Novartis Pharmaceuicals. Novartis receives FDA approval for Fabhalta\u00ae (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH [media release]. 6 Dec 2023. https:\/\/www.novartis.com."},{"key":"2009_CR7","unstructured":"Novartis Pharmaceuticals. Q2 2023 results: investor presentation. 2022. https:\/\/www.novartis.com\/. Accessed 18 Jan 2024."},{"key":"2009_CR8","unstructured":"Novartis Pharmaceuticals. Novartis pipeline as of December 31, 2022. 2022. https:\/\/www.novartis.com. Accessed 18 Jan 2024."},{"issue":"Suppl 1","key":"2009_CR9","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1182\/blood-2023-179655","volume":"142","author":"R Schmouder","year":"2023","unstructured":"Schmouder R, Junge G, Nidamarthy PK, et al. A first-in-human, phase 1 study to assess the pharmacodynamic properties of single-dose iptacopan (CLNP023X2101) [abstract]. Blood. 2023;142(Suppl 1):4096.","journal-title":"Blood"},{"issue":"15","key":"2009_CR10","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1182\/bloodadvances.2022006960","volume":"6","author":"JH Jang","year":"2022","unstructured":"Jang JH, Wong L, Ko BS, et al. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. Blood Adv. 2022;6(15):4450\u201360.","journal-title":"Blood Adv"},{"issue":"5","key":"2009_CR11","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1016\/S2352-3026(21)00028-4","volume":"8","author":"AM Risitano","year":"2021","unstructured":"Risitano AM, R\u00f6th A, Soret J, et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol. 2021;8(5):e344\u201354.","journal-title":"Lancet Haematol."},{"issue":"Suppl 1","key":"2009_CR12","doi-asserted-by":"publisher","first-page":"S360","DOI":"10.1016\/S2152-2650(23)01177-1","volume":"23","author":"AM Risitano","year":"2023","unstructured":"Risitano AM, Roth A, Kulasekararaj A, et al. Oral iptacopan monotherapy increases paroxysmal nocturnal hemoglobinuria (PNH) red blood cell clone size via control of intra- and extravascular hemolysis in anti-C5-treated PNH patients with anemia [abstract no. MDS-273]. Clin Lymphoma Myeloma Leuk. 2023;23(Suppl 1):S360.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 3","key":"2009_CR13","first-page":"189","volume":"7","author":"AM Risitano","year":"2023","unstructured":"Risitano AM, R\u00f6th A, Kulasekararaj A, et al. Oral iptacopan monotherapy increases paroxysmal nocturnal hemoglobinuria (PNH) red blood cell clone size via control of intra- and extravascular hemolysis in anti-C5-treated PNH patients with anemia [abstract no. S182]. HemaSphere. 2023;7(Suppl 3):189\u201390.","journal-title":"HemaSphere."},{"issue":"Suppl 1","key":"2009_CR14","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/blood-2023-178384","volume":"142","author":"M Zhang","year":"2023","unstructured":"Zhang M, Wang X, Yang C, et al. The change of complement deposition after complement inhibitor treatment in paroxysmal nocturnal hemoglobinuria patients [abstract]. Blood. 2023;142(Suppl 1):1350\u20131.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2009_CR15","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1182\/blood-2022-160114","volume":"140","author":"A Risitano","year":"2022","unstructured":"Risitano A, de Latour RP, Yap ES, et al. Dose-exposure-response relationships of biomarkers and efficacy measures with iptacopan, a complement factor b inhibitor, in patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) with or without concomitant anti-C5 therapy [abstract]. Blood. 2022;140(Suppl 1):5803\u20134.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2009_CR16","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1182\/blood-2023-180004","volume":"142","author":"I Baltcheva","year":"2023","unstructured":"Baltcheva I, Bartels C, Valentin M-A, et al. Exposure-response relationships between the factor B inhibitor iptacopan and complement biomarkers in healthy volunteers and patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3g) or IgA nephropathy (IgAN) [abstract]. Blood. 2023;142(Suppl 1):5640\u20131.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2009_CR17","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1182\/blood-2023-179960","volume":"142","author":"AM Risitano","year":"2023","unstructured":"Risitano AM, Peffault de Latour R, Jang JH, et al. exposure-response relationships between the complement factor B inhibitor iptacopan and lactate dehydrogenase (LDH) and hemoglobin (Hb) in patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) [abstract]. Blood. 2023;142(Suppl 1):5643.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2009_CR18","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1182\/blood-2023-179648","volume":"142","author":"R Schmouder","year":"2023","unstructured":"Schmouder R, Kaetterer N, Kulmatycki K, et al. A phase 1 study to assess the effect of supratherapeutic doses of iptacopan on cardiac conduction parameters and safety [abstract]. Blood. 2023;142(Suppl 1):5644.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2009_CR19","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1182\/blood-2023-179030","volume":"142","author":"A DeLise","year":"2023","unstructured":"DeLise A, Zamurovic N, Hansen R, et al. Results of preclinical animal studies to evaluate the effect of iptacopan on pregnancy-related outcomes [abstract]. Blood. 2023;142(Suppl 1):4094\u20135.","journal-title":"Blood"},{"issue":"7","key":"2009_CR20","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1124\/dmd.123.001290","volume":"51","author":"AD James","year":"2023","unstructured":"James AD, Kulmatycki K, Poller B, et al. Absorption, distribution, metabolism, and excretion of [14C]iptacopan in healthy male volunteers and in in vivo and in vitro studies. Drug Metab Dispos. 2023;51(7):873\u201383.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"2009_CR21","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","volume":"8","author":"E Wong","year":"2023","unstructured":"Wong E, Nester C, Cavero T, et al. Efficacy and safety of iptacopan in patients with C3 glomerulopathy. Kidney Int Rep. 2023;8(12):2754\u201364.","journal-title":"Kidney Int Rep."},{"issue":"Suppl 1","key":"2009_CR22","first-page":"i400","volume":"38","author":"R Schmouder","year":"2023","unstructured":"Schmouder R, Junge G, Nidamarthy P, et al. Japanese and Whites share similar iptacopan pharmacokinetics and pharmacodynamics [abstract no. 4463]. Nephrol Dial Transplant. 2023;38(Suppl 1):i400\u20131.","journal-title":"Nephrol Dial Transplant"},{"key":"2009_CR23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2022-171707","volume":"140","author":"RP de Latour","year":"2022","unstructured":"de Latour RP, Roeth A, Kulasekararaj A, et al. Oral monotherapy with iptacopan, a proximal complement inhibitor of Factor B, has superior efficacy to intravenous terminal complement inhibition with standard of care eculizumab or ravulizumab and favorable safety in patients with paroxysmal nocturnal hemoglobinuria and residual anemia: results from the randomized, active-comparator-controlled, open-label, multicenter, phase III APPLY-PNH study [abstract]. Blood. 2022;140:5\u20139.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2009_CR24","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1182\/blood-2023-180866","volume":"142","author":"AM Risitano","year":"2023","unstructured":"Risitano AM, Han B, Kulasekararaj A, et al. Categorization of hematological responses to oral iptacopan monotherapy in anti-C5-treated patients with paroxysmal nocturnal hemoglobinuria (PNH) and persistent anemia in the phase III APPLY-PNH trial and complement inhibitor-na\u00efve patients in the phase III APPOINT-PNH trial [abstract]. Blood. 2023;142(Suppl 1):4084\u20136.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2009_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1182\/blood-2023-179035","volume":"142","author":"AM Risitano","year":"2023","unstructured":"Risitano AM, de Castro CM, Han B, et al. Patient-reported improvements in fatigue and health-related quality of life in the phase 3 studies APPLY-PNH and APPOINT-PNH evaluating the use of iptacopan in C5 inhibitor-treated and treatment-na\u00efve patients with paroxysmal nocturnal hemoglobinuria [abstract]. Blood. 2023;142(Suppl 1):487.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2009_CR26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1182\/blood-2023-180780","volume":"142","author":"AM Risitano","year":"2023","unstructured":"Risitano AM, Kulasekararaj A, Roeth A, et al. Factor B inhibition with oral iptacopan monotherapy demonstrates sustained long-term efficacy and safety in anti-C5-treated patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) and persistent anemia: final 48-week results from the multicenter, phase III APPLY-PNH trial [abstract]. Blood. 2023;142(Suppl 1):571\u20135.","journal-title":"Blood"},{"issue":"Suppl 2","key":"2009_CR27","first-page":"173","volume":"45","author":"A R\u00f6th","year":"2022","unstructured":"R\u00f6th A, Peffault de Latour R, Soret J, et al. Use of the oral complement factor B inhibitor iptacopan in patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) with persistent hemolysis despite anti-C5 therapy: long-term efficacy and safety after stopping eculizumab (ECU) [abstract no. V576]. Oncol Res Treat. 2022;45(Suppl 2):173\u20134.","journal-title":"Oncol Res Treat."},{"key":"2009_CR28","unstructured":"Risitano A, Han B, Ueda Y, et al. Oral complement factor B inhibitor iptacopan monotherapy improves hemoglobin to normal\/near-normal levels in paroxysmal nocturnal hemoglobinuria patients na\u00efve to complement inhibitors: phase III APPOINT-PNH trial [abstract no. OS12-06]. In: 49th Annual Meeting of the European Society for Blood and Marrow Transplantation. 2023."},{"issue":"Suppl 1","key":"2009_CR29","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood-2021-152518","volume":"138","author":"J-H Jang","year":"2021","unstructured":"Jang J-H, Wong LLL, Ko B-S, et al. 12-month analysis of a phase 2 study of iptacopan (LNP023) monotherapy for paroxysmal nocturnal hemoglobinuria [abstract]. Blood. 2021;138(Suppl 1):2173\u20134.","journal-title":"Blood"},{"issue":"Suppl 1","key":"2009_CR30","doi-asserted-by":"publisher","first-page":"7339","DOI":"10.1182\/blood-2023-186840","volume":"142","author":"C De Castro","year":"2023","unstructured":"De Castro C, Scheinberg P, Han B, et al. Patient experience interviews with a novel treatment iptacopan for paroxysmal nocturnal hemoglobinuria [abstract]. Blood. 2023;142(Suppl 1):7339\u201341.","journal-title":"Blood"},{"issue":"Suppl 266","key":"2009_CR31","first-page":"31S","volume":"152","author":"M Meier","year":"2022","unstructured":"Meier M. An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy: interim analysis of a phase 2 study [abstract no OC 61]. Swiss Med Wkly. 2022;152(Suppl 266):31S-S32.","journal-title":"Swiss Med Wkly"},{"issue":"Suppl 3","key":"2009_CR32","first-page":"3967","volume":"7","author":"AM Risitano","year":"2023","unstructured":"Risitano AM, Araten DJ, Kuter D, et al. APPULSE-PNH: a phase IIIB trial to evaluate the efficacy and safety of switching to iptacopan in patients with paroxysmal nocturnal hemoglobinuria (PNH) on anti-C5 therapy with hemoglobin >10g\/dL [abstract no. PB2063]. HemaSphere. 2023;7(Suppl 3):3967\u20138.","journal-title":"HemaSphere."},{"key":"2009_CR33","doi-asserted-by":"publisher","DOI":"10.2217\/frd-2022-0020","author":"A Bomback","year":"2023","unstructured":"Bomback A. Design of the APPEAR-C3G study: a study to learn how well iptacopan works in people with complement 3 glomerulopathy. Future Rare Dis. 2023. https:\/\/doi.org\/10.2217\/frd-2022-0020.","journal-title":"Future Rare Dis."},{"issue":"1","key":"2009_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ekir.2023.10.022","volume":"9","author":"M Vivarelli","year":"2023","unstructured":"Vivarelli M, Bomback AS, Meier M, et al. Iptacopan in idiopathic immune complex\u2013mediated membranoproliferative glomerulonephritis: protocol of the APPARENT multicenter, randomized phase 3 study. Kidney Int Rep. 2023;9(1):64\u201372.","journal-title":"Kidney Int Rep."},{"issue":"7","key":"2009_CR35","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ekir.2023.04.029","volume":"8","author":"D Kavanagh","year":"2023","unstructured":"Kavanagh D, Greenbaum LA, Bagga A, et al. Design and rationale of the appelhus phase 3 open-label study of factor b inhibitor iptacopan for atypical hemolytic uremic syndrome. Kidney Int Rep. 2023;8(7):1332\u201341.","journal-title":"Kidney Int Rep."},{"issue":"5","key":"2009_CR36","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ekir.2023.01.041","volume":"8","author":"DV Rizk","year":"2023","unstructured":"Rizk DV, Rovin BH, Zhang H, et al. Targeting the alternative complement pathway with iptacopan to treat IgA nephropathy: design and rationale of the APPLAUSE-IgAN study. Kidney Int Rep. 2023;8(5):968\u201379.","journal-title":"Kidney Int Rep."}],"updated-by":[{"DOI":"10.1007\/s40265-024-02054-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02009-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02009-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02009-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T06:34:46Z","timestamp":1718951686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02009-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2009"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02009-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-024-02054-z","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,22]]},"assertion":[{"value":"12 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-024-02054-z","URL":"https:\/\/doi.org\/10.1007\/s40265-024-02054-z","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Yahiya Y. Syed is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}